Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

AstraZeneca

Status: Completed

Conditions: Hormon Receptor Positive Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01208779

NIS-ORS-DUM-2010/1

Details and patient eligibility

About

This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.

Enrollment: 90 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal females with estrogen receptor positive breast cancer that are currently treated with aromatase inhibitor (AI) medication
• Provision of subject informed consent

Exclusion criteria

• If participating in any clinical trial, the subject cannot take part in this study.

Trial design

90 participants in 1 patient group

1

Description:

Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study